Back to top

The Zacks Analyst Blog Highlights: Amazon, Celgene, Chubb, Delta and Merck

Read MoreHide Full Article

For Immediate Release

Chicago, IL – October 10, 2016 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amazon (NASDAQ:(AMZN - Free Report) -FreeReport), Celgene (NASDAQ:(CELG - Free Report) -Free Report), Chubb (NYSE:CB- Free Report), Delta (NYSE:(DAL - Free Report) -Free Report) and Merck (NYSE: (MRK - Free Report) - Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Amazon, Celgene, Chubb

Today's Research Daily features new research reports on 16 major stocks, including Amazon (NASDAQ:(AMZN - Free Report) -Free Report), Celgene (NASDAQ:(CELG - Free Report) -Free Report) and Chubb (NYSE:CB- Free Report).

Shares of Strong Buy rated Amazon have been strong performers lately (they are up more than 25% year-to-date), with analysts steadily raising estimates for this year and next. The analyst likes the manner in which Amazon is driving value across all its businesses despite the super-competitive nature of the retail business. With a number of major brick-and-mortar operators like Wal-Mart and others making concerted efforts in the online arena, Amazon has been able to capitalize on the secular growth in ecommerce with the help of not only choice and convenience but also prices. Also, the AWS generates much higher margins than retail, so it has a very positive impact on Amazon’s profitability. The company has a solid loyalty system in Prime and its FBA strategy, and content addition continues to add selection to Prime memberships. (You can read the full research report on Amazon here>>)

Celgene shares have been laggards this year, in line with the broader pharmaceutical space, reflecting political uncertainty around pricing issues. But the analyst likes buy-rated Celgene’s key growth driver, Revlimid, which continues to benefit from market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – should continue to drive the top line. The company’s raised outlook for 2016 is also encouraging. Meanwhile, label expansion of approved drugs would boost its revenues. Celgene’s pipeline also looks interesting with several data readouts expected in the second half of the year, and over the next few years. (You can read the full research report on Celgene here>>)

Chubb shares are up today, but they have struggled this year on broad macro issue notwithstanding, the analyst likes Chubb’s complementary products and services and its inorganic growth story. A strong capital position helps Chubb to engage in shareholder friendly moves and invest in strategic initiatives that drive growth. Recently, Chubb announced that its enterprise-wide insurance solution, Integrity+, will now be available in Canada. The latest policy will protect Canadian companies from errors and omissions (E&O) liability customer lawsuits. (You can read the full research report on Chubb here >>)

Other noteworthy reports we are featuring today include Delta (NYSE: (DAL - Free Report) -Free Report) and Merck (NYSE:(MRK - Free Report) - Free Report).

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. Today Steve is also opening up Zacks' 7 Best Stocks for October, 2016 free of charge. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>

You can find all of today's stock research reports here>>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on AMZN - FREE

Get the full Report on CELG - FREE

Get the full Report on CB - FREE

Get the full Report on DAL - FREE

Get the full Report on MRK - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

More from Zacks Press Releases

You May Like